Gamida Cell has named Julian Adams, Ph.D.—its current chair and chief scientific officer of Clal Biotech—as its new CEO.

The action marks the end for an oral adenosine A2a receptor antagonist Acorda paid $363 million in cash for last year.

Controversial plans to allow the Pentagon to approve drugs and medical devices intended for use by soldiers have been set aside in the latest version of the…

The framework builds on the 21st Century Cures Act by setting criteria for the RMAT designation and outlining the benefits of the regulatory status.

Ionis Pharmaceuticals has signed the rights to a second antisense drug over to Janssen for a fee of $5 million.

A Yale team has developed an alternative gene-editing technology that they say replaces CRISPR’s “hacksaw” effect with a more precise “scalpel.”

A protein that senses and responds to high cholesterol could serve as a new target for drug development.

Cancer and autoimmune startup Cue Biopharma has ended the year with a potentially lucrative new deal with Merck.